Mónica del Rey González-rekin lankidetzan egindako argitalpenak (10)

2024

  1. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8

    Cancers, Vol. 15, Núm. 15

2022

  1. MDS-454 SF3B1 and DNMT3A Mutations Might Play a Role in Poor Prognosis and AML Progression in Patients With Isolated del(5q) MDS

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S316

  2. MDS-472 STAG2 and SRSF2 Mutations Might Define Prognosis of MDS Patients With Isolated Trisomy 8

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S316-S317

2020

  1. Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

    Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671

2017

  1. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts

    Leukemia Research, Vol. 56, pp. 82-87

  2. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group

    American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541

2016

  1. Bone marrow fibrosis in myelodysplastic syndromes: A prospective evaluation including mutational analysis

    Oncotarget, Vol. 7, Núm. 21, pp. 30492-30503

2013

  1. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes

    Leukemia, Vol. 27, Núm. 3, pp. 610-618

  2. Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations

    British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86